Nanoscience Technologies, Inc. Contracts TVA Productions to Launch National and International MediaBlitz! Campaign
TVA's "MediaBlitz!." campaign http://media-blitz.tv/ for Nanoscience Technolgies, Inc. is designed to build awareness with the public and business community by mass dissemination of information on TV, print, radio and the Internet. The campaign includes production and nationwide distribution of a thirty minute TV Special Exclusive; a TV News Spotlight (2-8 min); Video News Release; In-Flight Video; Internet Streaming Video; 10-minute Corporate Video, DVD, Trade Show Loop Presentation; a sixty second Radio News Release, professionally recorded and distributed to over 6,000 Radio stations; and 1-3 column News Features with photo and contact info distributed to 10,000 newspapers reaching an estimated 20 million readers.
The TV programs will air for at least six months on national and local cable, satellite and broadcast affiliates throughout the U.S. Programs will air at least 1,000 times in primarily Top 50 markets between 6:30am and 10:30pm daily -- with the majority expected to be during primetime hours (5:30pm - 10:30pm). Over 90 million households will have access to the programming. The TV Spotlight will air daily on one or more major Airlines for at least one month as in-flight programming. A minimum of 100 Newspaper Feature placements and 200 Radio News Release placements are also guaranteed as part of the MediaBlitz!. package. Monthly updates of Nanoscience Technologies headlining events will appear in a major financial/business eNewsletter sent to over 650,000 opt-in subscribers including: 250,000+ financial services professionals, 50,000+ key corporate decision makers and 350,000+ investors.
TVA Productions, located in Studio City, California, http://www.tvaproductions.com, is one of the leading media production and news placement syndicates in N. America -- providing HD production & broadcast facilities, extensive distribution & tracking resources, and a worldwide staff. Since 1987, TVA has provided performance-based media booking services, national and local programming, and broadcast/print-ready News Features for over 20,000 TV, radio and print media outlets. TVA's "Pay Only for Results" services have been successfully used by Fortune 500 companies, emerging companies, ad agencies, PR firms (it's their best kept secret), national associations, non-profits, and government agencies worldwide. TVA's team has won over 40 Golden Mike, Addy, Emmy, Clio, Telly and Aegis awards. Clients include Baxter Medical, Canon, Cessna, Epson, Hill & Knowlton, LDS Church, Lexus, Marriott, Occidental Petroleum, Ogilvy, Princess Cruises, Qualcomm, Sony, Space Adventures, Technicolor, Teradata, Viseon, Westinghouse, World Vision, and Yonex.
About Nanoscience Technologies, Inc.
Nanoscience Technologies, Inc. combines business management, technology licensing and commercialization strategies to create a cohesive effort dedicated to delivering nanotechnology manufacturing solutions, nanodevices and nanomaterials to a wide range of industries worldwide. The Company's common equity is traded over-the-counter bulletin board (OTCBB:NANS).
The Company holds exclusive license rights to technology developed by New York University's (NYU) 'Seeman Laboratory' headed by Dr. Nadrian C. Seeman, the inventor of DNA-based nanoscience. Dr. Seeman is one of the foremost and recognized world leaders in DNA nanoscience research today and has been the recipient of many scientific awards. He is one of an elite few ever to be awarded the internationally prestigious Feynman Prize which he received in 1995. He is the author of over 200 published articles with more than 100 related to nanotechnology, 182 abstracts and oral presentations, and has been the recipient of numerous other scientific awards and industry citations for his excellence, prominence and contributions towards transforming the promise of nanotechnology into reality. More recently the Seeman Laboratory has developed and filed a patent application on a proprietary bi-pedal device (Note: This discovery has recently been covered in New Scientist, May 2004, and DiscoveryChannel.com). In addition, Dr Seeman was featured on the cover of the June 2004 Scientific American and had the lead article in that issue on DNA nanotechnology.
Structural DNA nanotechnology seeks to exploit the architectural properties of DNA with the ultimate goal of organizing matter in three dimensions. Pharmaceutical development, nano-electronics and the creation of new materials are among the initiatives and potential applications of this research. Nanoscience Technologies, Inc. now holds exclusive licensing rights to a portfolio of intellectual property from the Seeman Laboratory that has either been granted, filed, or pending. The primary building block of the Seeman Laboratory is using the DNA construct which is believed to be the best platform to achieve the systems and processes necessary to deliver nanotechnology products in many commercial arenas globally. For a list of issued patents, their outlines, and for more information on the company please go to: http://www.nanoscience-tech.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated by these statements. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new opportunities, and the unpredictable nature of business risks; as well as the ability to establish and grow brand awareness of NCHP and other factors set forth in the Company's most recently filed SEC reports. The forward-looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. The Company assumes no obligation to update the statements contained in this release.